Majid Hoseini1, Mehdi Sahmani2, Farshad Foroughi3,4, Yousef Khazaei Monfared1, Mehdi Azad5. 1. Department of medical biotechnology, School of Paramedicine, Qazvin University of Medical Sciences, Qazvin, Iran. 2. Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran. 3. Department of Immunology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. 4. Children Growth Research Center, Qazvin University of Medical Sciences, Qazvin, Iran. 5. Department of Medical laboratory sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
Abstract
BACKGROUND: Hypercoagulable states (HS) can result from several different inherited and acquired disease conditions that cause abnormalities in the genes, proteins and cellular factors involved in the coagulation cascade. Novel insight into the molecular mechanisms involved in the coagulation pathways can provide a framework to develop improved therapeutics to treat patients with coagulation disorders. Therefore, investigating the genetic abnormalities present in patients with coagulation disorders can offer critical insight into disease pathogenesis. Our study aimed to assess the promoter methylation patterns of the phosphatase and tensin homologue (PTEN) gene as a potential underlying factor involved in HS. METHODS: To measure the differences between the mRNA expression of PTEN in HS patients and healthy individuals we used qRT-PCR. Following bisulfite conversion, the promoter methylation status was analyzed using methylation specific PCR. The two-tailed student t-test was used to analyze the quantitative data. The data was considered statistically significant with a p value <0.05. RESULTS: Our findings reveal PTEN to be down-regulated by 30% in the blood samples of HS patients when compared to healthy controls. The MSP data showed the PTEN promoter region to be un-methylated in both patients and healthy individuals. CONCLUSION: Since no differences in the methylation patterns of the PTEN gene was found between HS patients and controls, this suggests that DNA methylation of the PTEN promoter may not be a significant contributing epigenetic modification involved in the development HS. However, MSP may not be able to detect subtle changes in DNA methylation status. Thus, using an alternative high resolution technique may more accurately indicate differences in the PTEN promoter methylation status in HS patients.
BACKGROUND: Hypercoagulable states (HS) can result from several different inherited and acquired disease conditions that cause abnormalities in the genes, proteins and cellular factors involved in the coagulation cascade. Novel insight into the molecular mechanisms involved in the coagulation pathways can provide a framework to develop improved therapeutics to treat patients with coagulation disorders. Therefore, investigating the genetic abnormalities present in patients with coagulation disorders can offer critical insight into disease pathogenesis. Our study aimed to assess the promoter methylation patterns of the phosphatase and tensin homologue (PTEN) gene as a potential underlying factor involved in HS. METHODS: To measure the differences between the mRNA expression of PTEN in HS patients and healthy individuals we used qRT-PCR. Following bisulfite conversion, the promoter methylation status was analyzed using methylation specific PCR. The two-tailed student t-test was used to analyze the quantitative data. The data was considered statistically significant with a p value <0.05. RESULTS: Our findings reveal PTEN to be down-regulated by 30% in the blood samples of HS patients when compared to healthy controls. The MSP data showed the PTEN promoter region to be un-methylated in both patients and healthy individuals. CONCLUSION: Since no differences in the methylation patterns of the PTEN gene was found between HS patients and controls, this suggests that DNA methylation of the PTEN promoter may not be a significant contributing epigenetic modification involved in the development HS. However, MSP may not be able to detect subtle changes in DNA methylation status. Thus, using an alternative high resolution technique may more accurately indicate differences in the PTEN promoter methylation status in HS patients.
Authors: Allen S Yang; Marcos R H Estecio; Guillermo Garcia-Manero; Hagop M Kantarjian; Jean-Pierre J Issa Journal: Science Date: 2003-11-14 Impact factor: 47.728
Authors: Yuan Rong; Dawn E Post; Russell O Pieper; Donald L Durden; Erwin G Van Meir; Daniel J Brat Journal: Cancer Res Date: 2005-02-15 Impact factor: 12.701
Authors: Joanne L Yu; Linda May; Vladimir Lhotak; Siranoush Shahrzad; Senji Shirasawa; Jeffrey I Weitz; Brenda L Coomber; Nigel Mackman; Janusz W Rak Journal: Blood Date: 2004-10-19 Impact factor: 22.113
Authors: Judit Pallares; Elena Bussaglia; Jose Luis Martínez-Guitarte; Xavier Dolcet; David Llobet; Montserrat Rue; Lidia Sanchez-Verde; Jose Palacios; Jaime Prat; Xavier Matias-Guiu Journal: Mod Pathol Date: 2005-05 Impact factor: 7.842
Authors: Mark P Ward; Laura E Kane; Sharon A O'Toole; John J O'Leary; Lucy A Norris; Bashir M Mohamed; Tanya Kelly; Mark Bates; Andres Clarke; Nathan Brady; Cara M Martin; Robert D Brooks; Doug A Brooks; Stavros Selemidis; Sean Hanniffy; Eric P Dixon Journal: Mol Cancer Date: 2021-03-31 Impact factor: 27.401